ACM Biolabs develops novel vaccines and antibodies using proprietary artificial cell membrane technology.
ACM Biolabs has raised $6.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.
ACM Biolabs's investors include Ritz Venture Capital.
ACM Biolabs is headquartered in Singapore, Singapore.
ACM Biolabs develops novel vaccines and antibodies using proprietary artificial cell membrane technology.
ACM Biolabs is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ACM Biolabs — Funding & Investors." VCBacked, September 22, 2022, https://www.vcbacked.co/company/acm-biolabs. Accessed September 29, 2026.
VCBacked. (2022). ACM Biolabs — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/acm-biolabs
{{cite web |title=ACM Biolabs — Funding & Investors |url=https://www.vcbacked.co/company/acm-biolabs |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated